Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed

Infection and Immunity

Volumn 81, Issue 7, 2013, Pages 2584-2591

  Ovsyannikova, Inna G ^a   Pankratz, V Shane ^a   Vierkant, Robert A ^a   Pajewski, Nicholas M ^b   Quinn, Conrad P ^c   Kaslow, Richard A ^d   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; HLA A ANTIGEN; HLA ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN;

ADULT; ARTICLE; CELLULAR IMMUNITY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HETEROZYGOTE ADVANTAGE; HLA SYSTEM; HOMOZYGOSITY; HUMAN; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALLELES; ANTHRAX; ANTHRAX VACCINES; ANTIBODY FORMATION; BACILLUS ANTHRACIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENETIC LOCI; HAPLOTYPES; HETEROZYGOTE; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HLA-DQ ALPHA-CHAINS; HLA-DQ BETA-CHAINS; HOMOZYGOTE; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; VACCINATION; YOUNG ADULT;

EID: 84879425164     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00269-13     Document Type: Article

References (42)

1. Brossier F, Weber-Levy M, Mock M, Sirard JC. 2000. Role of toxin functional domains in anthrax pathogenesis. Infect. Immun. 68:1781- 1786.
2. Cybulski RJ, Jr, Sanz P, O'Brien AD. 2009. Anthrax vaccination strategies. Mol. Aspects Med. 30:490 -502.
3. Williamson ED, Hodgson I, Walker NJ, Topping AW, Duchars MG, Mott JM, Estep J, Lebutt C, Flick-Smith HC, Jones HE, Li H, Quinn CP. 2005. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73:5978 -5987.
4. Little SF, Ivins BE, Webster WM, Fellows PF, Pitt ML, Norris SL, Andrews GP. 2006. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24:2530 -2536.
5. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M. 2006. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24: 5950-5959.
6. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. 2007. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum. Vaccin. 3:205-211.
7. Singer DE, Schneerson R, Bautista CT, Rubertone MV, Robbins JB, Taylor DN. 2008. Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U. S. military personnel. Vaccine 26:869-873.
8. Grabenstein JD. 2003. Anthrax vaccine: a review, p 713-730. In Poland GA (ed), Immunology and allergy clinics of North America: vaccines in the 21st century. WB Saunder Company, Philadelphia, PA.
9. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP. 2008. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 300:1532-1543.
10. Wright JG, Quinn CP, Shadomy S, Messonnier N. 2010. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep. 59(RR-6):1-30.
11. Crowe SR, Garman L, Engler RJ, Farris AD, Ballard JD, Harley JB, James JA. 2011. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine 29:3670 -3678.
12. Pajewski NM, Shrestha S, Quinn CP, Parker SD, Wiener H, Aissani B, McKinney BA, Poland GA, Edberg JC, Kimberly RP, Tang J, Kaslow RA. 2012. A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed. Vaccine 30:4778- 4784.
13. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Fernandez-Vina M, Geraghty DE, Holdsworth R, Hurley CK, Lau M, Lee KW, Mach B, Maiers M, Mayr WR, Muller CR, Parham P, Petersdorf EW, Sasazuki T, Strominger JL, Svejgaard A, Terasaki PI, Tiercy JM, Trowsdale J. 2010. Nomenclature for factors of the HLA system, 2010. Tissue Antigens 75:291- 455.
14. Pajewski NM, Parker SD, Poland GA, Ovsyannikova IG, Song W, Zhang K, McKinney BA, Pankratz VS, Edberg JC, Kimberly RP, Jacobson RM, Tang J, Kaslow RA. 2011. The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed. Genes Immun. 12:457- 465.
15. Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N. 2012. A three dose intramuscular schedule of Anthrax Vaccine Adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long term protection against inhalation anthrax in rhesus macaques. Clin. Vaccine Immunol. 19:1730 -1745.
16. Ovsyannikova IG, Ryan JE, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA. 2009. Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine 27:3359- 3366.
17. Ovsyannikova IG, Jacobson RM, Ryan JE, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA. 2005. HLA class II alleles and measles virusspecific cytokine immune response following two doses of measles vaccine. Immunogenetics 56:798-807.
18. Ovsyannikova IG, Jacobson RM, Vierkant RA, O'Byrne MM, Poland GA. 2009. Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine 27: 6926-6931.
19. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. 2004. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum. Immunol. 65:1506 -1515.
20. Ovsyannikova IG, Poland GA, Easler NJ, Vierkant RA. 2004. Influence of HLA-DRB1 alleles on lymphoproliferative responses to a naturally processed and presented measles virus phosphoprotein in measles immunized individuals. Hum. Immunol. 65:209 -217.
21. Ovsyannikova IG, Vierkant RA, Pankratz VS, O'Byrne MM, Jacobson RM, Poland GA. 2009. HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. Vaccine 27:3349 -3358.
22. St Sauver JL, Dhiman N, Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz SV, Jacobsen SJ, Poland GA. 2005. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measlesmumps-rubella vaccine. Hum. Immunol. 66:788 -798.
23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. 2002. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 70:425- 434.
24. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. 2007. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Ther. 82:653- 664.
25. Pati NT, Sukriti Hissar S, Agrawal K, Rani R, Sarin SK. 2007. Decrease in CD4+T lymphocyte proliferation responses and enhanced CD150 cell expression in health care workers non-responsive to HBV vaccine. Vaccine 25:1848 -1855.
26. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. 2004. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39:978 - 988.
27. Mustafa AS, Lundin KE, Oftung F. 1993. Human T cells recognize mycobacterial heat shock proteins in the context of multiple HLA-DR molecules: studies with healthy subjects vaccinated with Mycobacterium bovis BCG and Mycobacterium leprae. Infect. Immun. 61:5294 - 5301.
28. Kwok WW, Yang J, James E, Bui J, Huston L, Wiesen AR, Roti M. 2008. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-specific CD4+ T cells with a phenotype distinct from that of naive PA T cells. Infect. Immun. 76:4538-4545.
29. Ingram RJ, Metan G, Maillere B, Doganay M, Ozkul Y, Kim LU, Baillie L, Dyson H, Williamson ED, Chu KK, Ascough S, Moore S, Huwar TB, Robinson JH, Sriskandan S, Altmann DM. 2010. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. J. Immunol. 184:3814 -3821.
30. Davila J, McNamara LA, Yang Z. 2012. Comparison of the predicted population coverage of tuberculosis vaccine candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach. PLoS One 7:e40882. doi:10.1371/journal.pone.0040882.
31. Hraber PT, Kuiken C, Yusim K. 2007. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 46:1713-1721.
32. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283: 1748-1752.
33. Tang JM, Costello C, Keet IPM, Rivers C, LeBlanc S, Karita E, Allen S, Kaslow RA. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type I infection. AIDS Res. Hum. Retroviruses 15:317-324.
34. Thursz MR, Thomas HC, Greenwood BM, Hill AVS. 1997. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat. Genet. 17:11-12.
35. Seppänen M, Lokki ML, Timonen T, Lappalainen M, Jarva H, Jarvinen A, Sarna S, Valtonen V, Meri S. 2001. Complement C4 deficiency and HLA homozygosity in patients with frequent intraoral herpes simplex virus type 1 infections. Clin. Infect. Dis. 33:1604 -1607.
36. Burgner D, Jamieson SE, Blackwell JM. 2006. Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? Lancet Infect. Dis. 6:653- 663.
37. St Sauver JL, Ovsyannikova IG, Jacobson RM, Jacobsen SJ, Vierkant RA, Schaid DJ, Pankratz VS, Green EM, Poland GA. 2002. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J. Infect. Dis. 185:1545-1549.
38. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. 1989. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321:708 -712.
39. Jacobson RM, Ovsyannikova IG, Vierkant RA, Shane P, Poland VGA. 2011. Human leukocyte antigen associations with humoral and cellular immunity following a second dose of measles-containing vaccine: persistence, dampening, and extinction of associations found after a first dose. Vaccine 29:7982-7991.
40. Kennedy RB, Ovsyannikova IG, Vierkant RA, Jacobson RM, Poland GA. 2010. Effect of human leukocyte antigen homozygosity on rubella vaccine-induced humoral and cell-mediated immune responses. Hum. Immunol. 71:128 -135.
41. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17:1055-1065.
42. Quinn CP, Sabourin CL, Mittler R, Wrammert J, Schiffer J, Li H, Semenova V, Parker S, Babcock J, Keitel W, Poland GA, Keyserling H, Plikaytis B, Wright J. 2010. Humoral antibody and immune cell responses to reduced schedules of anthrax vaccine absorbed in humans, abstr 104(H),p67. Program and abstracts of the ASM Biodefense and Emerging Diseases Research Meeting. American Society for Microbiology, Washington, DC.